Reverse immunoediting: When immunity is edited by antigen
- PMID: 27131431
- DOI: 10.1016/j.imlet.2016.04.015
Reverse immunoediting: When immunity is edited by antigen
Abstract
Immune selective pressure occurring during cancer immunoediting shapes tumor features revealed at clinical presentation. However, in the "Escape" phase, the tumor itself has the chance to influence the immunological response. Therefore, the capacity of the immune response to sculpt the tumor characteristics is only one side of the coin and even the opposite is likely true, i.e. that an antigen can shape the immune response in a sort of "reverse immunoediting". This reciprocal modeling probably occurs continuously, whenever the immune system encounters a tumor/foreign antigen, and can be operative in the pathogen/immune system interplay, thus possibly permeating the protective immunity as a whole. In line with this view, the characterization of a T cell response as well as the design of both active and passive immunotherapy strategies should also take into account all Ag features (type, load and presentation). Overall, we suggest that the "reverse immunoediting" hypothesis could help to dissect the complex interplay between antigens and the immune repertoire, and to improve the outcome of immunotherapeutic approaches, where T cell responses are manipulated and reprogrammed.
Keywords: Antigen; Cancer; Immunodominance; Immunoediting; Immunotherapy; Virus.
Copyright © 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Cancer immunotherapy: moving forward with peptide T cell vaccines.Curr Opin Immunol. 2017 Aug;47:57-63. doi: 10.1016/j.coi.2017.07.003. Epub 2017 Jul 19. Curr Opin Immunol. 2017. PMID: 28734176 Free PMC article. Review.
-
Cancer Neoantigens.Annu Rev Immunol. 2019 Apr 26;37:173-200. doi: 10.1146/annurev-immunol-042617-053402. Epub 2018 Dec 14. Annu Rev Immunol. 2019. PMID: 30550719 Review.
-
[Antitumor immunity and cellular cancer therapies].Med Sci (Paris). 2003 Jan;19(1):43-53. doi: 10.1051/medsci/200319143. Med Sci (Paris). 2003. PMID: 12836191 Review. French.
-
Challenges and prospects of immunotherapy as cancer treatment.Biochim Biophys Acta. 2007 Sep;1776(1):108-23. doi: 10.1016/j.bbcan.2007.07.003. Epub 2007 Jul 17. Biochim Biophys Acta. 2007. PMID: 17720322 Review.
-
Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.Med Res Rev. 2008 May;28(3):413-44. doi: 10.1002/med.20110. Med Res Rev. 2008. PMID: 17694549 Review.
Cited by
-
miRNA-218/FANCI is associated with metastasis and poor prognosis in lung adenocarcinoma: a bioinformatics analysis.Ann Transl Med. 2021 Aug;9(16):1298. doi: 10.21037/atm-21-3823. Ann Transl Med. 2021. PMID: 34532435 Free PMC article.
-
Survival Advantage Following TAG-72 Antigen-Directed Cancer Surgery in Patients With Colorectal Carcinoma: Proposed Mechanisms of Action.Front Oncol. 2021 Dec 7;11:731350. doi: 10.3389/fonc.2021.731350. eCollection 2021. Front Oncol. 2021. PMID: 34950576 Free PMC article.
-
Key microRNAs and hub genes associated with poor prognosis in lung adenocarcinoma.Aging (Albany NY). 2021 Jan 10;13(3):3742-3762. doi: 10.18632/aging.202337. Epub 2021 Jan 10. Aging (Albany NY). 2021. PMID: 33461176 Free PMC article.
-
The chemistry and efficacy benefits of polysaccharides from Atractylodes macrocephala Koidz.Front Pharmacol. 2022 Aug 25;13:952061. doi: 10.3389/fphar.2022.952061. eCollection 2022. Front Pharmacol. 2022. PMID: 36091757 Free PMC article. Review.
-
Prediction and verification of benignancy and malignancy of pulmonary nodules based on inflammatory related biological markers.Heliyon. 2024 Jul 21;10(15):e34585. doi: 10.1016/j.heliyon.2024.e34585. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39144966 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources